News

Brianna Oddi, Pharm.D. Brianna Oddi, Pharm.D., is senior clinical account manager of PANTHERx Rare Pharmacy

Carly Rodriguez, Pharm.D., is vice president and chief pharmacy officer, Moda Health and immediate past president of the Academy of Managed Care Pharmacy

Alyana Samai, M.P.H., is corporate vice president, neuroscience and musculoskeletal services, at LCMC Health, an eight-hospital, New Orleans-based nonprofit health system.

Lorece Shaw, Pharm.D., is director of clinical account consulting at Capital Rx, a pharmacy benefit and management company.

The second-line drug for metastatic pancreatic cancer is pan-RAS inhibitor that recruits cyclophilin A to stick to RAS proteins, explains Subham Pant, M.D., M.B.B.S., of The University of Texas MD Anderson Cancer Center.

Javier Cortes, M.D., Ph.D., discusses KEYNOTE-522 findings showing pembrolizumab plus chemotherapy delivers durable survival gains in high-risk early-stage TNBC after nearly 8 years of follow-up.

Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.

Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B.B.S.

Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody that achieved 28-month median survival in advanced squamous non-small cell lung cancer.

Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.

A new investigational combination therapy for advanced KRAS G12C-mutant non-small cell lung cancer showed "highly promising" results with “manageable” side effects, according to the study’s lead author.

Ferdinandos Skoulidis, M.D., Ph.D., explains what’s next for this treatment for patients with previously untreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, according to the results of the Krascendo 170 study, presented today at ASCO 2026.

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.

A collagen implant that releases radiation after brain tumor surgery reduced cancer recurrence and increased overall survival, according to results presented at ASCO’s annual meeting.

Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.

Seven-year CROWN trial data show lorlatinib's median PFS still not reached in advanced ALK-positive NSCLC, with a 94% reduction in intracranial progression risk.

Afrezza is an inhaled insulin and the first needle-free insulin option for children with diabetes.

Because pharmacy benefit managers and third-party administrators earn more from arrangements with smaller safety-net providers, there are incentives to shift attribution of prescriptions toward those providers.

Eli Lilly and Company is acquiring three vaccine companies to expand its reach into infectious disease research and prevention.

Hepcludex is an antiviral to treat adults living with chronic hepatitis D virus infection, a serious liver disease that occurs as a co-infection in people with chronic hepatitis B virus.

Nubeqa (darolutamide) may have fewer negative cognitive side effects because it doesn't cross the blood-brain barrier.

Women with high-grade serous ovarian cancer who fasted around chemotherapy sessions had lower insulin levels, improved chemotherapy responses and potentially longer progression-free survival compared with patients who ate normally, according to findings from an Italian study presented at the 2026 American Society of Clinical Oncology Annual Meeting.

GLP-1 receptor agonist drugs may reduce cancer progression in lung, breast, colorectal, and liver cancers by 38% to 50%, and high GLP-1 receptor expression correlates with 33% lower mortality risk.

By targeting a specific pathway, the mineralocorticoid receptor, Kerendia is able to stop the cascade of inflammation and fibrosis that leads to kidney disease.